Serum high-density lipoprotein is associated with better cognitive function in a cross-sectional study of aging women

International Journal of Neuroscience

Volumn 127, Issue 3, 2017, Pages 243-252

  Bates, Kristyn A ^a,b,c   Sohrabi, Hamid R ^a,b,c,d   Rainey Smith, Stephanie R ^a,b   Weinborn, Michael ^a,b,c   Bucks, Romola S ^c   Rodrigues, Mark ^a,b   Beilby, John ^c,e   Howard, Matthew ^a   Taddei, Kevin ^a,b   Martins, Georgia ^a,b   Paton, Athena ^a   Shah, Tejal ^b   Dhaliwal, Satvinder S ^f   Foster, Jonathan K ^f   Martins, Ian J ^a,b   Lautenschlager, Nicola T ^c,g   Mastaglia, Frank L ^h   Gandy, Samuel E ⁱ   Martins, Ralph N ^a,b,c  

^a EDITH COWAN UNIVERSITY   (Australia)

^b McCusker Foundation for Alzheimer's Disease Research Inc   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d Cooperative Research Centre for Mental Health ^*  (Australia)

^e PATHWEST LABORATORY MEDICINE   (Australia)

^f CURTIN UNIVERSITY   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h MURDOCH UNIVERSITY   (Australia)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

ageing; apolipoprotein E; cognitive function; high density lipoprotein; memory; women

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BIOCHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; COGNITION; CROSS-SECTIONAL STUDY; DEMENTIA; DEPRESSION; EPISODIC MEMORY; FEMALE; GENETIC ANALYSIS; HUMAN; LEARNING; MENTAL DETERIORATION; MENTAL PERFORMANCE; MILD COGNITIVE IMPAIRMENT; PROTEIN BLOOD LEVEL; RISK FACTOR; BLOOD; COGNITIVE AGING; COHORT ANALYSIS; GENETICS; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; REGRESSION ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AGING; APOLIPOPROTEINS E; COGNITION; COGNITIVE AGING; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIPOPROTEINS, HDL; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; REGRESSION ANALYSIS; VERBAL LEARNING;

EID: 84966769758     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.1080/00207454.2016.1182527     Document Type: Article

References (78)

1. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe:a collaborative study of population-based cohorts. Neurol Dis Elderly Res Group Neurol 2000;54(11 Suppl 5):S4–9.
2. Carter CL, Resnick EM, Mallampalli M, Kalbarczyk A. Sex and gender differences in Alzheimer's disease:recommendations for future research. J Womens Health (Larchmt) 2012;21(10):1018–23. doi:10.1089/jwh.2012.3789.
3. Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. J Am Med Assoc 1995;273(17):1354–9.
4. Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer's disease:assessing sex and gender differences. Clin Epidemiol 2014;6:37–48. doi:10.2147/CLEP.S37929.
5. Norton S, Matthews FE, Barnes DE, et al. Potential for primary prevention of Alzheimer's disease:an analysis of population-based data. Lancet Neurol 2014;13(8):788–94. doi:10.1016/S1474-4422(14)70136-X.
6. Luck T, Luppa M, Matschinger H, et al. Incident subjective memory complaints and the risk of subsequent dementia. Acta Psychiatr Scand 2015;131(4):290–6. doi:10.1111/acps.12328.
7. Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement 2014;10(6):844–52. doi:10.1016/j.jalz.2014.01.001.
8. Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry 2000;15(11):983–91.
9. Montejo P, Montenegro M, Fernandez MA, Maestu F. Subjective memory complaints in the elderly:prevalence and influence of temporal orientation, depression and quality of life in a population-based study in the city of Madrid. Aging Ment Health 2011;15(1):85–96. doi:10.1080/13607863.2010.501062.
10. Barnes LL, Schneider JA, Boyle PA, et al. Memory complaints are related to Alzheimer disease pathology in older persons. Neurology 2006;67(9):1581–5.
11. Merrill DA, Siddarth P, Saito NY, et al. Self-reported memory impairment and brain PET of amyloid and tau in middle-aged and older adults without dementia. Int Psychogeriatr 2012;24(7):1076–84. doi:10.1017/S1041610212000051.
12. Palmer K, Backman L, Winblad B, Fratiglioni L. Detection of Alzheimer's disease and dementia in the preclinical phase:population based cohort study. Brit Med J 2003;326(7383):245.
13. Mitchell AJ, Beaumont H, Ferguson D, et al. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints:meta-analysis. Acta Psychiatr Scand 2014;130(6):439–51. doi:10.1111/acps.12336.
14. Laske C, Sohrabi HR, Frost SM, et al. Innovative diagnostic tools for early detection of Alzheimer's disease. Alzheimers Dement 2015;1(5):561–578. doi:10.1016/j.jalz.2014.06.004.
15. Henderson, VW., Estrogen, cognition, and a woman's risk of Alzheimer's disease. Am J Med 1997;103(3A):11S–8S.
16. Bonithon-Kopp C, Scarabin PY, Darne B, et al. Menopause-related changes in lipoproteins and some other cardiovascular risk factors. Int J Epidemiol 1990;19(1):42–8.
17. Gustafson D, Rothenberg E, Blennow K, et al. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 2003;163(13):1524–8.
18. Hartmann, T. Cholesterol, A beta and Alzheimer's disease. Trends Neurosci 2001;24(11 Suppl):S45–8.
19. Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005;62(10):1556–60.
20. Gustafson D, Lissner L, Bengtsson C, et al. A 24-year follow-up of body mass index and cerebral atrophy. Neurology 2004;63(10):1876–81.
21. Martins IJ, Hone E, Foster JK, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 2006;11(8):721–36.
22. Yaffe K, Weston AL, Blackwell T, Krueger KA. The metabolic syndrome and development of cognitive impairment among older women. Arch Neurol 2009;66(3):324–8. doi:10.1001/archneurol.2008.566.
23. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev 2016;1:CD003160. doi:10.1002/14651858.CD003160.pub3.
24. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261(5123):921–3.
25. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide:isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90(17):8098–102.
26. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43(8):1467–72.
27. Risacher SL, Kim S, Nho K, et al. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimers Dement 2015;11(12):1417–29. doi:10.1016/j.jalz.2015.03.003.
28. Sohrabi HR, Bates KA, Rodrigues M, et al. The relationship between memory complaints, perceived quality of life and mental health in apolipoprotein Eepsilon4 carriers and non-carriers. J Alzheimers Dis 2009;17(1):69–79. doi:10.3233/JAD-2009-1018.
29. Jonker C, Schmand B, Lindeboom J, et al. Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol 1998;55(8):1065–9.
30. Salmon DP, Ferris SH, Thomas RG, et al. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology 2013;27(4):391–401. doi:10.1037/a0032707
31. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. Framingham Study JAMA 1986;256(20):2835–8.
32. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. J Am Med Assoc 2007;298(7):776–85. doi:10.1001/jama.298.7.776.
33. Johnson LA, Sohrabi HR, Hall JR, et al. A depressive endophenotype of poorer cognition among cognitively healthy community-dwelling adults:results from the Western Australia memory study. Int J Geriatr Psychiatry 2015;30(8):881–886. doi:10.1002/gps.4231.
34. Bates KA, Sohrabi HR, Rodrigues M, et al. Association of cardiovascular factors and Alzheimer's disease plasma amyloid-beta protein in subjective memory complainers. J Alzheimers Dis 2009;17(2):305–18. doi:10.3233/JAD-2009-1050.
35. Roth M, Tym E, Mountjoy CQ, et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986;149:698–709.
36. Geerlings MI, Jonker C, Bouter LM, et al. Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am J Psychiatry 1999;156(4):531–7.
37. Schofield PW, Jacobs D, Marder K, et al. The validity of new memory complaints in the elderly. Arch Neurol 1997;54:756–9.
38. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale:a preliminary report. J Psychiatr Res 1982;17(1):37–49.
39. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189–98.
40. Beardsall L., Development of the Cambridge contextual reading test for improving the estimation of premorbid verbal intelligence in older persons with dementia. Br J Clin Psychol 1998;37(Pt 2):229–40.
41. Delis DC, Freeland J, Kramer JH, Kaplan E. Integrating clinical assessment with cognitive neuroscience:construct validation of the California Verbal Learning Test. J Consult Clin Psychol 1988;56(1):123–30.
42. Barnes DE, Yaffe K, Satariano WA, Tager IB. A longitudinal study of cardiorespiratory fitness and cognitive function in healthy older adults. J Am Geriatr Soc. 2003;51(4):459–65.
43. Greenaway MC, Lacritz LH, Binegar D, et al. Patterns of verbal memory performance in mild cognitive impairment, Alzheimer disease, and normal aging. Cogn Behav Neurol 2006;19(2):79–84.
44. Lundervold AJ, Wollschlager D, Wehling E. Age and sex related changes in episodic memory function in middle aged and older adults. Scand J Psychol 2014;55(3):225–32. doi:10.1111/sjop.12114.
45. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31(3):545–8.
46. Laws SM, Clarnette RM, Taddei K, et al. APOE-epsilon4 and APOE-491A polymorphisms in individuals with subjective memory loss. Mol Psychiatry 2002;7(7):768–75.
47. Tonkin A, Barter P, Best J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand:position statement on lipid management–2005. Heart Lung Circ 2005;14(4):275–91. doi:10.1016/j.hlc.2005.10.010.
48. Delis DC, Kramer JH, Kaplan A, Ober NA. CVLT-II California Verbal Learning Test Manual Adult version. 2nd ed. Oxford:Harcourt Assessment Inc.; 2000.
49. Cooper C, Sommerlad A, Lyketsos CG, Livingston G. Modifiable predictors of dementia in mild cognitive impairment:a systematic review and meta-analysis. Am J Psychiatry 2015;172(4):323–34. doi:10.1176/appi.ajp.2014.14070878.
50. Xu W, Tan L, Wang HF, et al. Meta-analysis of modifiable risk factors for Alzheimer's disease. J Neurol Neurosurg Psychiatry 2015;86(12):1299–306. doi:10.1136/jnnp-2015-310548.
51. Chen P, Ratcliff G, Belle SH, et al. Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. Neurology 2000;55(12):1847–53.
52. Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer's disease in memory-impaired patients:a prospective longitudinal study. Neurology 1996;46(3):661–5.
53. Weintraub S, Wicklund AH, Salmon DP. The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med 2012;2(4):a006171. doi:10.1101/cshperspect.a006171.
54. Zhang J, McKeown RE, Hajjar I. Serum cholesterol levels are associated with impaired recall memory among older people. Age Ageing 2005;34(2):178–82.
55. van Exel E, de Craen AJ, Gussekloo J, et al. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol 2002;51(6):716–21. doi:10.1002/ana.10220.
56. Singh-Manoux A, Gimeno D, Kivimaki M, et al. Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife. Whitehall II Study Arterioscler Thromb Vasc Biol 2008;28:1557–63.
57. Komulainen P, Lakka TA, Kivipelto M, et al. Metabolic syndrome and cognitive function:a population-based follow-up study in elderly women. Dement Geriatr Cogn Disord 2007;23(1):29–34.
58. Atzmon G, Gabriely I, Greiner W, et al. Plasma HDL levels highly correlate with cognitive function in exceptional longevity. J Gerontol A Biol Sci Med Sci 2002;57(11):M712–5.
59. de Frias CM, Bunce D, Wahlin A, et al. Cholesterol and triglycerides moderate the effect of apolipoprotein E on memory functioning in older adults. J Gerontol B Psychol Sci Soc Sci 2007;62(2):P112–8.
60. Solomon A, Kareholt I, Ngandu T, et al. Serum cholesterol changes after midlife and late-life cognition:twenty-one-year follow-up study. Neurology 2007;68(10):751–6.
61. Leritz EC, McGlinchey RE, Salat DH, Milberg WP. Elevated levels of serum cholesterol are associated with better performance on tasks of episodic memory. Metab Brain Dis 2016. doi:10.1007/s11011-016-9797-y.
62. Koudinov AR, Berezov TT, Kumar A, Koudinova NV. Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein:association with apolipoprotein and lipids. Clin Chim Acta 1998;270(2):75–84.
63. Wilson LM, Pham CL, Jenkins AJ, et al. High density lipoproteins bind Abeta and apolipoprotein C-II amyloid fibrils. J Lipid Res 2006;47(4):755–60.
64. Biere AL, Ostaszewski B, Stimson ER, et al. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 1996;271(51):32916–22.
65. Cole GM, Beech W, Frautschy SA, et al. Lipoprotein effects on Abeta accumulation and degradation by microglia in vitro. J Neurosci Res 1999;57(4):504–20.
66. Lovestone S, Anderton BH, Hartley C, et al. The intracellular fate of apolipoprotein E is tau dependent and apoe allele-specific. Neuroreport 1996;7(5):1005–8.
67. Kounnas MZ, Moir RD, Rebeck GW, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995;82(2):331–40.
68. Dong LM, Wilson C, Wardell MR, et al. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem 1994;269(35):22358–65.
69. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364(2):127–35. doi:10.1056/NEJMoa1001689.
70. Ward MA, Bendlin BB, McLaren DG, et al. Low HDL cholesterol is associated with lower gray matter volume in cognitively healthy adults. Front Aging Neurosci 2010;2:1–8. doi:10.3389/Fnagi.2010.00029.
71. Wolf H, Hensel A, Arendt T, et al. Serum lipids and hippocampal volume:the link to Alzheimer's disease? Ann Neurol 2004;56(5):745–8.
72. Olesen OF, Dago L. High density lipoprotein inhibits assembly of amyloid beta-peptides into fibrils. Biochem Biophys Res Commun 2000;270(1):62–6.
73. Mauch DH, Nagler K, Schumacher S, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001;294(5545):1354–7.
74. Cockerill GW, Reed S. High-density lipoprotein:multipotent effects on cells of the vasculature. Int Rev Cytol 1999;188:257–97.
75. Paterno R, Ruocco A, Postiglione A, et al. Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc Dis 2004;17(2–3):204–11. doi:10.1159/000075792.
76. Craig SR, Amin RV, Russell DW, Paradise NF. Blood cholesterol screening–influence of fasting state on cholesterol results and management decisions. J Gen Internal Med 2000;15(6):395–9. doi:10.1046/j.1525-1497.2000.03509.x.
77. Harrison SL, Stephan BC, Siervo M, et al. Is there an association between metabolic syndrome and cognitive function in very old adults? The Newcastle 85+ study. J Am Geriatr Soc 2015;63(4):667–75. doi:10.1111/jgs.13358.
78. Corley J, Starr JM, Deary IJ. Serum cholesterol and cognitive functions:the Lothian birth cohort 1936. Int Psychogeriatr 2015;27(3):439–53. doi:S1041610214001197.